The US FDA has removed the clinical hold on a trial of Cialis (tadalafil) by Sanofi's consumer healthcare business, Opella.

A guiding service offers a pricey drug therapy (that's also illegal in professional sports) to get clients to the Everest ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...

Sanofi announces new Sarclisa subcutaneous formulation meets co-primary endpoints in IRAKLIA phase 3 study in multiple myeloma: Paris Friday, January 10, 2025, 15:00 Hrs [IST] Res ...

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple ...

Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

The Thistle will open its doors next week after nearly a decade of deadlock over drug laws. The Thistle will open its doors next week after nearly a decade of deadlock over drug laws. Naloxone is ...

Mounjaro (tirzepatide) is a prescription drug that’s used to treat type 2 diabetes. The drug comes as a liquid solution that you inject under your skin, typically once per week. Mounjaro ...